Last reviewed · How we verify
GP681 Powder for Oral Suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GP681 Powder for Oral Suspension (GP681 Powder for Oral Suspension) — Jiangxi Qingfeng Pharmaceutical Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GP681 Powder for Oral Suspension TARGET | GP681 Powder for Oral Suspension | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GP681 Powder for Oral Suspension CI watch — RSS
- GP681 Powder for Oral Suspension CI watch — Atom
- GP681 Powder for Oral Suspension CI watch — JSON
- GP681 Powder for Oral Suspension alone — RSS
Cite this brief
Drug Landscape (2026). GP681 Powder for Oral Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/gp681-powder-for-oral-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab